Summary of FibroBiologics Special Meeting of Stockholders Company Overview - **Company**: FibroBiologics (NasdaqGM:FBLG) - **Industry**: Biotechnology, specifically focusing on regenerative medicine and fibroblast technology Key Points from the Meeting Corporate Governance - The meeting was presided over by Pete O'Heeron, Founder, Chairman, and CEO, with other board members and executives present [2][17] - A quorum was established with 54,971,343 votes representing approximately 56% of the total votes available [5] Proposals Voted On 1. **Reverse Stock Split**: Proposal to amend the certificate of incorporation for a reverse stock split at a ratio between 1-for-5 and 1-for-30, approved [9][15] 2. **Issuance of Shares**: Multiple proposals to approve the issuance of shares upon the exercise of outstanding common warrants, all approved: - Up to 12,110,203 shares from a securities purchase agreement dated November 18, 2025 [10][15] - Up to 4,477,614 shares from agreements dated November 24, 2025, and 313,433 shares from an engagement letter dated November 10, 2025 [11][15] - Up to 5,227,275 shares from agreements dated December 14, 2025, and 365,909 shares from an engagement letter [12][15] 3. **Adjournment of Meeting**: Approved to solicit additional votes if necessary [13][15] Corporate Update Highlights - **Mission**: To harness the immune modulation and regenerative potential of fibroblasts to treat and cure chronic diseases [18] - **Clinical Trials**: - Currently conducting a Phase 1/2 clinical trial for diabetic foot ulcers [19] - IND submitted for psoriasis at the end of December 2025, with plans for IND-ready assets for multiple sclerosis and degenerative disc disease [19] - **Financial Position**: Clean balance sheet with $4.9 million in cash as of September 30, 2025, and over 270 issued and pending patents [19][20] Technology and Innovation - **Fibroblast Technology**: - Fibroblasts are positioned as a promising alternative to stem cells for regenerative medicine due to their regenerative and immune-modulating properties [21][22] - Fibroblasts are abundant, well-characterized, and offer advantages in non-invasive sourcing, immune modulation, and cost-effectiveness [22][23] - **Pipeline**: Focus on diabetic foot ulcers, multiple sclerosis, degenerative disc disease, and psoriasis, with potential applications in longevity and cancer treatment [30][31][32] Market Opportunity - **Diabetic Foot Ulcers**: Approximately 33 million diabetes patients develop diabetic foot ulcers, representing a significant commercial opportunity [24] - **Multiple Sclerosis**: Affects 2.9 million globally, with a focus on addressing root causes rather than just symptom management [27] - **Psoriasis**: Affects 123 million worldwide, with current treatments being inadequate; fibroblast modulation offers a new approach [30] Future Outlook - The company aims to become a leader in regenerative medicine, focusing on impactful innovations rather than size [19] - Plans to advance clinical trials and potentially bring products to market rapidly, contingent on FDA approvals and trial results [36] Additional Insights - The meeting emphasized the importance of innovation, teamwork, and a commitment to curing chronic diseases rather than merely managing symptoms [19][20] - The leadership team has over 60 years of combined experience in medical innovation and capital markets, providing strategic guidance for the company's direction [20] This summary encapsulates the key discussions and proposals from the FibroBiologics special meeting, highlighting the company's strategic focus on fibroblast technology and its potential to transform the treatment of chronic diseases.

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 20, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("the Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced that, subject to approval from the TSX, the Company intends to amend some of its outstanding warrants.The Company issued 20,852,100 warrants pursuant to a private placement unit offering on Sep ...

Core Insights - Adia Nutrition Inc. is expanding its clinical research pipeline with plans to launch four to five new studies in 2026, focusing on regenerative therapies using Adia Vita, which is derived from umbilical cord blood [1][4]. Clinical Research Expansion - The planned studies will be conducted at the Adia Med clinic in Winter Park, Florida, and in collaboration with partner clinics across the U.S. [3] - The company is actively seeking Institutional Review Board (IRB) approvals to facilitate multi-site participation for these studies [3][4]. Focus Areas of New Studies - Priority efforts include expanding the existing Autism Spectrum Disorder (ASD) study to include children aged 13, and launching a new study on the effects of Adia Vita in patients with rheumatoid arthritis [8]. - The ongoing ASD study is actively recruiting children aged 3-12 and has received IRB approval [4]. Business Model and Revenue Generation - Adia Nutrition generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments [9]. - The company is also investing in aligned businesses, such as Cement Factory LLC, to enhance its focus on health and wellness [9]. Commitment to Ethical Standards - All research conducted by Adia Med is under strict ethical oversight, informed consent, and regulatory compliance [5]. - The company emphasizes its commitment to advancing regenerative medicine through rigorous and ethical clinical research [4]. Strategic Partnerships - Adia Med is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing its name or integrating its regenerative therapies into their practices [6]. - Collaborations with leading clinics are aimed at accelerating IRB approvals and broadening patient access [4].

Core Insights - The company reported a Q4 adjusted EBITDA margin of 20.8% and adjusted diluted EPS of $0.69, with a year-over-year margin decline attributed to lower test and measurement volume and higher operating expenses [1] - The company experienced stable to improving trends across most end markets, with adjusted EBITDA and adjusted EPS at or above the high end of guidance ranges, and a robust free cash flow conversion of 117% for the full year [2] - The company anticipates 2025 to be a pivotal year, focusing on long-term strategy, innovation, and culture enhancement post-separation, with Q4 revenue of $555 million, reflecting a 1% year-over-year increase [3] Financial Performance - Q4 revenue was $555 million, exceeding guidance, with a 1% year-over-year increase and a 5% sequential growth [4][3] - The company recorded a $1.4 billion non-cash goodwill impairment related to the Elektro-Automatik acquisition due to weakened EV demand and industry forecasts [6][9] - Free cash flow for Q4 was $92 million, with a full-year conversion rate of 117%, and the company ended the quarter with $319 million in cash and 1.9x net leverage [7][8] Guidance and Outlook - For 2026, the company guided revenue of $2.1 to $2.2 billion, an adjusted EBITDA margin of 18% to 20%, and adjusted EPS of $2.22 to $2.42, noting near-term margin pressure from structural costs and increased reinvestment [5][22] - The first quarter of 2026 is expected to see revenue between $508 million and $522 million, representing 5% to 8% year-over-year growth [18] - The company expects a sequential quarterly revenue increase throughout 2026, with adjusted EBITDA margin reflecting a year-over-year decline due to structural cost changes post-spin [18] Strategic Initiatives - The company is focusing on three strategic pillars: operating discipline through the Ralliant Business System, deepening market positions, and expanding in growth vectors such as defense, energy, and electronics [13] - Organic reinvestment is prioritized, with CapEx expected to be 2%-3% of revenue in 2026, up from about 2% historically [14] - The company has authorized a quarterly cash dividend of $0.05 per share and has a $200 million share repurchase authorization remaining [15] Segment Performance - In Q4, organic revenue was flat year-over-year, with pricing actions and healthy demand in Sensors and Safety Systems offset by lower test and measurement volume [11] - The Sensors and Safety Systems segment saw a 6% year-over-year revenue increase, while the Test and Measurement segment experienced a 6% year-over-year decline [16]

Core Viewpoint - Apollo Biowellness, Inc. has terminated its Exclusive Distribution Agreement with Revive Regenerative, Inc. and is shifting its strategy to manage distribution and marketing internally [1][4]. Group 1: Termination of Agreement - The Exclusive Distribution Agreement between Evolutionary Biologics and Revive Regenerative has been terminated for cause, as disclosed to Revive [1]. - The termination allows Apollo Biowellness to resume management of its distribution and marketing efforts through its own initiatives and non-exclusive agreements [3]. Group 2: Strategic Direction - The company is moving in a new direction, with plans to announce further details shortly [4]. - Jim Morrison, the founder of Apollo Biowellness, is returning as CEO to lead the company in this new direction [4]. Group 3: Company Overview - Apollo Biowellness, Inc. and its subsidiary, Evolutionary Biologics, focus on the discovery, development, and marketing of products aimed at improving human health, particularly in the field of Regenerative Medicine [5]. - The company is developing natural stem cell mobilizing agents and a dual acting diet aid, targeting both consumer and professional markets [5].

Core Viewpoint - Adia Nutrition Inc. has achieved a significant milestone by having its Form 10 registration statement become effective, transitioning the company to full reporting status under SEC regulations, which enhances transparency and prepares for potential uplisting to NASDAQ [1][2][3] Group 1: Company Developments - The Form 10 was filed on December 5, 2025, and became effective automatically 60 days later without further SEC review, marking a transition to full reporting status [2] - CEO Larry Powalisz emphasized that this achievement reflects the company's commitment to governance and investor confidence, while also accelerating preparations for uplisting to NASDAQ [3] - The company is expanding its regenerative medicine platform and clinic network, focusing on advanced treatments in stem cell therapy [3] Group 2: Financial and Operational Highlights - Adia Nutrition generates revenue through service fees, product sales, equity stakes, and insurance billing for healthcare treatments [7] - The company is experiencing significant revenue growth and operational expansion in 2025, positioning itself for continued momentum in personalized healthcare [8] - Adia Nutrition is also investing in aligned businesses, such as Cement Factory LLC, which focuses on health and wellness [7] Group 3: Strategic Partnerships and Initiatives - The company is encouraging clinic owners and healthcare practitioners to license the Adia Med name or integrate its regenerative therapies into their practices [5] - Adia Nutrition is forming strategic partnerships to expand access to advanced stem cell solutions [5] - The company is involved in ongoing clinical studies, including an IRB-approved study on autism spectrum disorder using regenerative stem cell therapy [8]

Core Insights - Adia Nutrition Inc. has appointed Dr. Brian L. Browning as the lead physician for orthopedic treatments at Adia Med, enhancing its leadership in regenerative medicine and orthopedic specialties [1][6][8] Group 1: Company Overview - Adia Nutrition Inc. is based in Winter Park, Florida, and is publicly traded, focusing on advancing healthcare through innovative regenerative medicine solutions [8] - The company specializes in stem cell and regenerative products, including AdiaVita and AdiaLink, and is expanding its offerings to include insurance-billable wound care products [8][9] - Adia Med clinics provide specialized treatments in orthopedic care, pain management, and wound repair, integrating advanced regenerative therapies [8][9] Group 2: Leadership and Expertise - Dr. Browning has extensive experience in orthopedic regenerative treatments and a strong background in family medicine and neuromusculoskeletal medicine [4][5] - He has been involved in training physicians and has a patient-centered approach, which positions Adia Med to offer comprehensive non-surgical regenerative solutions [6][8] Group 3: Services and Treatments - Under Dr. Browning's leadership, Adia Med will offer advanced regenerative treatments such as stem cell therapy, platelet-rich plasma (PRP) therapy, and ultrasound-guided injections for various orthopedic conditions [5][6] - The clinic's services are designed to integrate seamlessly with Adia Med's flagship stem cell therapies, focusing on pain management, sports injuries, and tissue regeneration [5][6] Group 4: Strategic Partnerships and Growth - Adia Nutrition Inc. is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating its regenerative therapies [7] - The company aims to expand access to advanced stem cell solutions as part of its mission to revolutionize healthcare and promote holistic wellness [9]

Core Insights - Regentis Biomaterials Ltd. is expanding its U.S. clinical site network to enhance its infrastructure for ongoing and future clinical programs [1] - The company has surpassed 50% patient enrollment in its pivotal Phase III study of GelrinC® for knee cartilage repair [1] - GelrinC is positioned to transform the cartilage repair market with its off-the-shelf regenerative products [1] Company Developments - The expansion of clinical sites is expected to accelerate patient enrollment in the ongoing Phase III study [1] - The new sites will also support future clinical programs beyond the current study [1] Industry Impact - GelrinC is anticipated to significantly impact the cartilage repair market by providing innovative regenerative solutions [1]

Core Insights - Adia Nutrition Inc. is set to release a documentary featuring professional wrestler Jeff Sciullo's recovery from a tricep injury, highlighting the effectiveness of its regenerative therapy product, AdiaVita [1][3][5] Company Overview - Adia Nutrition Inc. is based in Winter Park, Florida, and is publicly traded under the ticker OTCQB: ADIA, focusing on advancing healthcare through innovative stem cell and regenerative products [8] - The company operates through its lab division, Adia Labs LLC, and is expanding its services to include insurance-billable wound care products [8] - Adia Med clinics specialize in orthopedic, pain management, and wound repair, offering advanced regenerative treatments such as stem cell therapies and platelet-rich plasma (PRP) [8] Product Details - AdiaVita is a high-potency stem cell product that delivers over 100 million umbilical cord-derived stem cells and more than 3 trillion exosomes per dose, aimed at promoting rapid tissue repair and reducing recovery time for athletes [1][5] - The documentary will showcase the real-world results of the AdiaVita treatment, emphasizing its role in accelerating healing and improving recovery outcomes in sports medicine [5][6] Strategic Partnerships - The documentary is produced in collaboration with The Dr. Asa Network, which is known for its focus on health media and regenerative medicine, enhancing the visibility of Adia's treatments [3][5] - Adia Nutrition Inc. is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating its regenerative therapies into their practices [7] Revenue Generation - The company generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments, indicating a diversified income stream [9] - Adia Nutrition Inc. also invests in aligned businesses, such as Cement Factory LLC, which focuses on health and wellness, further expanding its market presence [9]

Core Insights - Ernexa Therapeutics has been selected as one of ten companies globally to participate in the Japan Entry Acceleration Program (JEAP), highlighting its innovative cell therapy platform for advanced cancer and autoimmune diseases [1][2]. Group 1: Company Overview - Ernexa Therapeutics focuses on developing novel cell therapies, particularly using induced pluripotent stem cells (iPSCs) to create allogeneic synthetic induced mesenchymal stem cells (iMSCs), which provide scalable treatment solutions [7]. - The company’s lead products include ERNA-101, aimed at enhancing the immune system's ability to target tumors, and ERNA-201, which addresses harmful inflammation in autoimmune diseases [5][8]. Group 2: Program Participation - JEAP is a competitive initiative by the Japan External Trade Organization (JETRO), attracting around 70 companies from 25 countries, emphasizing the high level of competition [2][6]. - Participation in JEAP offers Ernexa access to expert mentoring, market-entry guidance, and opportunities for collaboration with leading Japanese research and development organizations [4][6]. Group 3: Strategic Goals - The program is expected to advance Ernexa's pipeline in Japan, with ERNA-101 entering first-in-human clinical trials for ovarian cancer this year, addressing significant unmet needs in cancer treatment [5]. - The company aims to leverage JEAP to explore strategic partnerships and clinical development opportunities, ultimately striving to deliver hope to patients with serious conditions [3].